Friday, February 09, 2007

Gilead And Achillion End Hepatitis Drug Development

Shares of Achillion Pharmaceuticals Inc. (ACHN) plummeted $9.17 to $8.82 after its partnership with Gilead Sciences Inc. (GILD) to develop a hepatitis drug was halted. Gilead stock lost $1.26 to $70.90.

0 Comments:

Post a Comment

<< Home